• Login
    View Item 
    •   Home
    • Graduate Theses, Dissertations and Projects
    • Queen's Graduate Theses and Dissertations
    • View Item
    •   Home
    • Graduate Theses, Dissertations and Projects
    • Queen's Graduate Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    A PILOT STUDY: AN OPEN-LABEL BIOMARKER DEVELOPMENT OF KETAMINE FOR UNIPOLAR REFRACTORY DEPRESSION

    Thumbnail
    View/Open
    Thesis document (1.141Mb)
    Author
    Kang, Melody
    Metadata
    Show full item record
    Abstract
    Objective: The primary objective of this study is to evaluate the antidepressant efficacy of an acute intravenous subanesthetic ketamine treatment (0.5 mg/kg) for patients with unipolar treatment-resistant depression (TRD). The secondary objective of this study is to identify peripheral blood-based biomarkers associated with response to treatment. Method: Fifteen adults diagnosed with TRD completed an open-label study of repeated infusions of low dose ketamine (0.5 mg/kg) over the course of four weeks. Blood was collected from eleven patients at three time points throughout the acute treatment to analyze peripheral biomarkers including irisin, IL-6, IL-10, TNF-α, and BDNF. Results: Repeated ketamine infusions produced a significant decrease in total average MADRS scores in fifteen patients with unipolar TRD [F(1, 14) = 49.06, p<0.01] at all timepoints. Improvements in depressive symptoms were significant at one-week [t(14)=9.32, p<0.01], and continued to significantly decrease until two-weeks [t(14)=2.27, p<0.05]. The antidepressant effect was maintained for the entire duration of treatment. Psychiatric symptoms measured by the BPRS significantly decreased throughout treatment, which correlated to the decrease in MADRS scores (r=0.99, p<0.01). Ketamine was generally well-tolerated, and we observed improvements in functional impairment and anhedonia with no increases in manic symptoms. Levels of BDNF throughout treatment significantly correlated to decreases in MADRS scores (r=-0.66, p<0.05), and baseline BDNF levels predicted mood response at one- [F(1, 10) = 12.23, p<0.01] and four-weeks [F(1, 10) = 9.55, p<0.05]. Conclusion: Repeated subanesthetic doses of ketamine infusions significantly improve depressive symptoms and produce sustained antidepressant effects over four weeks of treatment. Ketamine may be an efficacious and safe pharmacological option for the acute treatment of patients suffering from severe treatment-resistant depression, and BDNF has the potential to function as a prognostic biomarker for predicting response to ketamine treatments.
    URI for this record
    http://hdl.handle.net/1974/28125
    Collections
    • Centre for Neuroscience Studies Graduate Theses
    • Queen's Graduate Theses and Dissertations
    Request an alternative format
    If you require this document in an alternate, accessible format, please contact the Queen's Adaptive Technology Centre

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us
    Theme by 
    Atmire NV
     

     

    Browse

    All of QSpaceCommunities & CollectionsPublished DatesAuthorsTitlesSubjectsTypesThis CollectionPublished DatesAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    View Usage StatisticsView Google Analytics Statistics

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us
    Theme by 
    Atmire NV